Shares in US biotech Five Prime Therapeutics more than tripled after it reported promising trial results with stomach cancer drug candidate bemarituzumab, returning the stock to levels not seen ...

Amgen is to buy US biotech Five Prime Therapeutics for around $1.9 billion, adding a potential gastric cancer drug to its pipeline. The big pharma swooped in after the California biotech reported ...

AHF, based in Los Angeles, said Prime Therapeutics lowered its payment rates ... The arbitrator referred to evidence showing $2.5 billion of cost savings that reflected the nationwide reduction ...